These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 22327308)
1. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines. Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308 [TBL] [Abstract][Full Text] [Related]
2. [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin]. Chen JF; Jin J Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):890-3. PubMed ID: 20193325 [TBL] [Abstract][Full Text] [Related]
3. [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells]. Qian ZZ; Wang HQ; Fu K; Ma YL; Hao XS Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):47-51. PubMed ID: 21429402 [TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295 [TBL] [Abstract][Full Text] [Related]
5. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799 [TBL] [Abstract][Full Text] [Related]
6. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267 [TBL] [Abstract][Full Text] [Related]
7. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726 [TBL] [Abstract][Full Text] [Related]
8. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Horton TM; Gannavarapu A; Blaney SM; D'Argenio DZ; Plon SE; Berg SL Cancer Chemother Pharmacol; 2006 Jul; 58(1):13-23. PubMed ID: 16292537 [TBL] [Abstract][Full Text] [Related]
13. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Valentiner U; Haane C; Nehmann N; Schumacher U Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367 [TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280 [TBL] [Abstract][Full Text] [Related]
15. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib induces apoptosis in human neuroblastoma CHP126 cells. Luo P; Lin M; Lin M; Zhu D; Wang Z; Shen J; Yang B; He Q Pharmazie; 2010 Mar; 65(3):213-8. PubMed ID: 20383943 [TBL] [Abstract][Full Text] [Related]
17. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109 [TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
19. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. Luo P; Lin M; Li L; Yang B; He Q PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]